Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.60 |
| ▸ | EGFR | P00533 | 10/20 | 0.60 |
| ▸ | ABL1 | P00519 | 7/20 | 0.60 |
| ▸ | ABL2 | P42684 | 7/20 | 0.60 |
| ▸ | CDK1 | P06493 | 6/20 | 0.60 |
| ▸ | KDR | P35968 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CSK | P41240 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783292 | 0.86 | SRC (0.60) | SRCLMNAMAPTKMT2AKDM4E | |
| SCHEMBL2783182 | 0.86 | LMNA (0.55) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL7842356 | 0.86 | SRC (0.82) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL7843429 | 0.84 | SRC (0.70) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL2784114 | 0.84 | LMNA (0.48) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL7847666 | 0.83 | SRC (0.62) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL2782773 | 0.82 | LMNA (0.61) | SRCEGFRLMNAMAPTKMT2A | |
| SCHEMBL2784322 | 0.80 | LMNA (0.49) | SRCLMNAMAPTKMT2AKDM4E | |
| SCHEMBL20911902 | 0.80 | MAPT (0.83) | SRCLMNAMAPTKMT2AKDM4E | |
| SCHEMBL2785296 | 0.79 | LMNA (0.58) | SRCEGFRLMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144758-A1 | AZAINDOLE P2X3 AND P2X2/3 MODULATORS | DILLON MICHAEL PATRICK | 2010-06-10 | — | — | US | claimed |
| WO-2010066629-A2 | NOVEL AZAINDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | WO | disclosed |
| US-20100144758-A1 | AZAINDOLE P2X3 AND P2X2/3 MODULATORS | DILLON MICHAEL PATRICK | 2010-06-10 | — | — | US | disclosed |
| US-20100144758-A1 | AZAINDOLE P2X3 AND P2X2/3 MODULATORS | DILLON MICHAEL PATRICK | 2010-06-10 | — | — | US | disclosed |
| US-20100144758-A1 | AZAINDOLE P2X3 AND P2X2/3 MODULATORS | DILLON MICHAEL PATRICK | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144758-A1 | AZAINDOLE P2X3 AND P2X2/3 MODULATORS | P2RX3, P2RX2, P2RX7 | SRC 2083/4885EGFR 3044/4885ABL1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.